This indicates that the search for AD biomarkers can benefit from the consideration of genetic risk above and beyond APOE. Different biomarkers could point to different pathway involvement, which could allow clinical trials to stratify patients accordingly. The gene discussed is APOE; the disease is Alzheimer disease.